What is the clinical evidence from this study?

Study design: Review. Population: Duchenne muscular dystrophy. Intervention: Antisense oligonucleotide therapies (eteplirsen, golodirsen, viltolarsen, casimersen).

June 24, 2026RNA BiologyOpen Access

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook

View Full Paper

Ask AI

Bookmark

Key result

ASO therapies restore dystrophin to ~6% of normal in DMD despite debated clinical benefit.

Population

Patients with Duchenne muscular dystrophy (DMD)

Design

Review

Authors

HMHidenori MoriyamaUniversity of Alberta SMShiori MoriyamaTokyo Metropolitan Children's Medical Center TYToshifumi YokotaUniversity of Alberta

Discussion

Member takes

Implication

Guides DMD exon-skipping therapy selection among four approved ASOs; leaves open long-term efficacy questions from post-marketing data.

Key Points

This review aims to provide an overview of FDA-approved antisense oligonucleotide therapies for Duchenne muscular dystrophy and their implications.
Comprehensive overview of four FDA-approved ASO therapies: eteplirsen, golodirsen, viltolarsen, and casimersen.
Analysis of clinical trials, post-marketing updates, and ongoing confirmatory trials.
Discussion of the challenges in clinical trial design and real-world effectiveness.
Identified four FDA-approved ASO therapies with varying clinical efficacy and patient eligibility issues.
Highlighted ongoing debates regarding the FDA's accelerated approval process based on limited data.
Outlined future research goals focusing on next-generation ASOs to improve therapeutic outcomes.

Structured PICO

Population

Patients with Duchenne muscular dystrophy (DMD)

Intervention

FDA-approved antisense oligonucleotide (ASO) therapies (eteplirsen, golodirsen, viltolarsen, and casimersen)

This review provides a comprehensive overview of FDA-approved ASO therapies for DMD, emphasizing the need for confirmatory trials and next-generation ASOs to achieve definitive clinical outcomes.

Limitations

Complexities in clinical trial design including small sample sizes and open-label phases
Discrepancies between preclinical efficacy and clinical outcomes
Limited patient eligibility restricted to specific exon mutations
Accelerated FDA approvals based on limited surrogate biomarker data rather than proven clinical benefit
Difficulty in quantifying trace amounts of restored dystrophin with high precision
complexities in clinical trial design
discrepancies between preclinical efficacy and clinical outcomes
real-world burdens
limited patient eligibility

Cite This Study

Moriyama et al. (2026) conducted a review in Duchenne muscular dystrophy. Antisense oligonucleotide therapies (eteplirsen, golodirsen, viltolarsen, casimersen) was evaluated. Antisense oligonucleotide therapies for Duchenne muscular dystrophy restore modest dystrophin levels (e.g., <1% to ~6% of normal), though definitive clinical benefit remains under ongoing debate.

synapsesocial.com/papers/6a3c232cd15afadd906f9de1 https://doi.org/10.1080/15476286.2026.2689117

View Full Paper

Ask AI

Bookmark

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider